Observation On The Curative Effect Of Yiqi Jianxin Decoction Combined With Sacubitril/Valsartan In The Treatment Of Congestive Heart Failure

Objective:In this study,Yiqi Jianxin Decoction combined with Sacubitril/Valsartan(SAC/VAL)was used in the treatment of Congestive heart failure(CHF)with cardiopulmonary deficiency,blood stasis and water cessation syndrome.Observed the effect of the treatment plan on the patients with this disease,and objectively evaluated its clinical efficacy and safety,it was expected to safely and effectively improve the clinical symptoms of CHF patients and improve their quality of life,further lower the hospitalization rate and mortality rate,and provide new ideas for the clinical treatment of CHF with integrated traditional Chinese and western medicine.Content:The aim of this study was to observe the efficacy of Yiqi Jianxin Decoction in the treatment of CHF and evaluate the clinical effect and safety of its combination with SAC/VAL.The TCM syndrome score(including single symptom scores and total scores),left ventricular ejection fraction(LVEF),N-terminal pro-brain natriuretic peptide(NT-pro BNP),New York Heart Association(NYHA)classification and other routine safety indicators were observed before and after treatment.Analyze and compare the test results,and the final conclusions were drawn.Methods:According to the principle of randomized controlled trial,60 subjects included in this study were divided into control group and experimental group,with 30 cases in each group.The control group was treated with basic treatment including sacubitril/valsartan,and the experimental group was treated with Yiqi Jianxin Decoction on the basis of the control group.After 12 weeks of treatment and follow-up,the results of observation indicators before and after treatment were recorded,and the data were statistically analyzed by SPSS 27.0 to evaluate the efficacy and safety of this study.Results:1.TCM syndrome scores:Statistical analysis of the scores of single TCM symptoms in each group showed that except for abdominal distension,the other 9 symptoms in the experimental group were significantly improved(P﹤0.01).In the control group,palpitation,shortness of breath,chest tightness(pain),floating face and swollen limbs,and oliguria were also improved to varying degrees.Comparing the scores of single symptoms before and after treatment between the two groups,the experimental group had more significant curative effect than the control group in improving palpitation,shortness of breath,chest tightness(pain),fatigue,sweating,floating face and swollen limbs,and oliguria symptoms(P﹤0.05).Before treatment,there was no statistical significance in total scores of CHF patients between the difference of two groups(P﹥0.05).After treatment,scores of both groups were significantly improved(P﹤0.01),and scores of experimental group were better improved(P﹤0.05).After treatment,the syndrome efficacy between the two groups was compared according to the syndrome score.Compared with the control group,the syndrome efficacy of the experimental group was significantly better(P ﹤ 0.01).2.NYHA cardiac function classification:There was no statistical significance in the difference of cardiac function between the two groups of CHF patients before treatment(P﹥0.05).The experimental group had better improvement in cardiac function classification than the other group after treatment(P﹤0.01).In terms of cardiac function,the curative effect of the experimental group was significantly better than the other group(P﹤0.01).3.LVEF:Before treatment,there was no statistical significance in LVEF level between the difference of two groups(P﹥0.05).After treatment,LVEF levels of CHF patients in each group were significantly improved(P﹤0.01),and compared with the control group,the experimental group had better curative effect(P ﹤ 0.05).4.NT-pro BNP:Before treatment,there was no statistical significance in NT-pro BNP level of CHF patients between the difference of two groups(P﹥0.05).After treatment,NT-pro BNP was highly improved in both groups(P﹥0.01),and the experimental group had a better improvement(P﹤0.05).5.In terms of safety,all CHF patients in both groups had no adverse events during treatment.Conclusion: Yiqi Jianxin Decoction combined with SAC/VAL can effectively treat CHF with cardiopulmonary deficiency,blood stasis and water cessation syndrome,which can significantly improve the symptoms of heart failure,reduce NT-pro BNP level to a certain extent,improve NYHA cardiac function classification,and improve LVEF of patients.It is an effective drug for the treatment of CHF and improve its prognosis.